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Abstract
Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is accepted as a predictive biomarker for the selection of
immune checkpoint inhibitors. We evaluated the staining quality and estimation of the tumor proportion score (TPS) in non-
small-cell lung cancer during two external quality assessment (EQA) schemes by the European Society of Pathology. Participants
received two tissue micro-arrays with three (2017) and four (2018) cases for PD-L1 IHC and a positive tonsil control, for staining
by their routine protocol. After the participants returned stained slides to the EQA coordination center, three pathologists assessed
each slide and awarded an expert staining score from 1 to 5 points based on the staining concordance. Expert scores significantly
(p < 0.01) improved between EQA schemes from 3.8 (n = 67) to 4.3 (n = 74) on 5 points. Participants used 32 different protocols:
the majority applied the 22C3 (56.7%) (Dako), SP263 (19.1%) (Ventana), and E1L3N (Cell Signaling) (7.1%) clones. Staining
artifacts consisted mainly of very weak or weak antigen demonstration (63.0%) or excessive background staining (19.8%).
Participants using CE-IVD kits reached a higher score compared with those using laboratory-developed tests (LDTs) (p < 0.05),
mainly attributed to a better concordance of SP263. The TPS was under- and over-estimated in 20/423 (4.7%) and 24/423 (5.7%)
cases, respectively, correlating to a lower expert score. Additional research is needed on the concordance of less common
protocols, and on reasons for lower LDT concordance. Laboratories should carefully validate all test methods and regularly
verify their performance. EQA participation should focus on both staining concordance and interpretation of PD-L1 IHC.
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FFPE Formalin-fixed paraffin embedded
EGFR Epidermal growth factor receptor
EMA European Medicines Agency
ESP European Society of Pathology
GEE Generalized estimating equations
IHC Immunohistochemistry
ICI Immune Checkpoint Inhibitors
IRR Incidence rate ratio
ISO International Organization for Standardization
NSCLC Non-small-cell lung cancer
OR Odds ratio
PD-1 Programmed cell death protein 1
PD-L1 Programmed death ligand 1
RT Room temperature
RTU Ready-to-use
TPS Tumor proportion score
TMA Tissue micro-array
Introduction
Several immune-checkpoint inhibitors (ICIs) have emerged
which target the programmed cell death protein 1 (PD-1)/pro-
grammed death ligand 1 (PD-L1) interaction in non-small-cell
lung cancer (NSCLC), such as the anti-PD-1 drugs nivolumab
and pembrolizumab [1–4], and the PD-L1 inhibitors
atezolizumab and durvalumab [5, 6]. The efficacy of ICIs in
NSCLC has been shown in various clinical trials, and PD-L1
immunohistochemistry (IHC) has been widely accepted as a pre-
dictive biomarker because of its association with increased effi-
cacy of ICIs [7, 8]. Both nivolumab and atezolizumab have been
approved by the Food and Drug Administration (FDA) and the
EuropeanMedicines Agency (EMA) [9, 10] as second-line ther-
apy irrespective of PD-L1 expression. Treatment with
pembrolizumab requires at least 50% of PD-L1 positive tumor
cells in a first-line setting for stage IV NSCLC patients or those
with stage III disease who cannot be treated by chemotherapy or
radiation therapy [3, 4]. Recently, the FDA approved
durvalumab asmaintenance therapy in patients with unresectable
stage III NSCLC without progression after concurrent chemora-
diotherapy [11], irrespective of the PD-L1 status. The EMA,
however, has restricted this indication to patients with PD-L1
on ≥ 1% of tumor cells [12].
Four commercial assays are currently available, each for a
specific drug and applying a specific tumor proportion score
(TPS) threshold for positivity. The Ventana PD-L1 (SP142)
Assay, Ventana PD-L1 (SP263) Assay, and the PD-L1 IHC
22C3 pharmDx (Agilent Technologies/Dako) kit are CE-
marked in vitro diagnostic (CE-IVD) labeled [13] and have
been validated in the clinical trials for atezolizumab,
pembrolizumab or durvalumab, and pembrolizumab only, re-
spectively. The 22C3 kit and SP263 assay have also been
approved as compan ion d iagnos t i c s (CDx) fo r
pembrolizumab by the FDA [14] and received a CE-IVD cer-
tification in Europe [13], respectively, while the other kits are
considered as complementary diagnostics [15].
Several studies have compared these assays, and reported
similar analytical sensitivities of the 22C3, 28-8, and SP263
assays with good inter-observer concordance for TPS, but
highlighted a lower sensitivity of the SP142 assay in this con-
text [16–22]. In another study, 14/38 (37%) of cases received
another clinical classification of the PD-L1 status depending
on which assay/scoring system was used when comparing
22C3, 28-8, SP142, and SP263 [18].
Due to the wide variety in commercially available plat-
forms, their concomitant implementation in one laboratory
would result in increased costs and a limited number of
NSCLC being tested on more than one platform.
Laboratories may also opt to use a laboratory developed test
(LDT), such as E1L3N or QR1 primary antibodies, or the use
of the antibodies described above with a different protocol
than the CE-IVD certified ones. Comparison of LDTs to ref-
erence CE-IVD assays yielded varying results ranging from
52% to 54% concordance to even 85% or 100 % [17, 23]. To
date, however, there remains confusion about the range of
assays which are fit-for-purpose for PD-L1 testing for individ-
ual drugs and the interchangeability between them.
Irrespective of the protocol used, laboratories are required
to appropriately verify or validate their PD-L1 IHC test, to
take part in continuous quality monitoring and participation
to External Quality Assessment (EQA) [24–26]. Lower stain-
ing concordance for LDTs compared with CE-IVD approved
assays was reported by two other EQA providers [27–29], but
participants’ interpretation of the TPS was not always
assessed [27]. The aim of this study is to evaluate the results
of assessment of the staining concordance of PD-L1 IHC and
its influence on TPS estimations, for the different (LDT or
CDx approved) methods in two subsequent EQA schemes
of the European Society of Pathology (ESP).
Laboratory characteristics have shown to affect the EQA
performance for other markers in NSCLC [30], but not yet for
the technical assessment of PD-L1 concordance with optimal
reference stains. Therefore, we also aimed to evaluate how
different laboratory characteristics influence concordance
rates. Finally, we provide an overview of most common stain-
ing artifacts observed for our EQA participants.
Material and methods
Two EQA schemes were organized in 2017 (pilot) and 2018,
both accredited for International Organization for
Standardization (ISO) 17043:2010 [31] and open to all labo-
ratories worldwide. Participants received two unstained
formalin-fixed paraffin embedded (FFPE) slides of 3-μm
thickness from a tissue micro-array (TMA) containing three
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(2017) and four (2018) cases from archival FFPE NSCLC
resection specimens (collected 7.4–76.4 months prior to dis-
tribution) and a positive tonsil control. In 2017, one large core
per case was provided. In 2018, three cores with a diameter of
2 mmwere punched for every case. Any one or a combination
of the three cores per case could be used for interpretation of
the TPS. Hematoxylin and eosin stained slides of parallel sec-
tions were made digitally available to enable assessment of
tissue morphology, preservation, and the minimum number of
tumor cells. To select a sample set with varying TPS and
determine the ground truth, samples were pretested by a cen-
tral accredited reference laboratory [26] with 22C3 (Dako) or
SP263 (Ventana) according to manufacturer’s instructions
(Supplemental Figure 1).
Participants were requested to stain the slides according to
their routine protocol within 14 calendar days after sample
receipt and to send the stained slides back to the EQA provid-
er. The maximum time between cutting of the slides and stain-
ing by the participants was 1 month. An electronic datasheet
was completed including information on the laboratory char-
acteristics, applied methodology, and estimation of the TPS
(in categories of < 1%, 1–50%, or > 50%).
A team of three pathologists assessed the stains simulta-
neously under a multi-head microscope for the staining con-
cordance, based on pre-defined scoring criteria. Prior harmo-
nization was performed for equal assessment on slides with an
excellent concordance with the reference stain for a specific
antibody. Each participant stain was compared with the opti-
mal reference stain and relative to stains from international
peers. An expert staining score (ESS) ranging from 1 to 5
points was awarded based on the staining concordance of all
cases with the reference slides, corresponding to 5: Excellent
concordance for the specific protocol, 4: Concordant staining
with minor remark, 3: Non-concordant staining without af-
fecting clinical output, 2: Non-concordant staining affecting
clinical output, 1: Failed, uninterpretable staining.
At the end of the scheme, participants received online ex-
amples of optimally concordant stains and corresponding pro-
tocols, a general scheme summary on sample outcomes (TPS)
and ESS, and individual comments on their individual stain-
ing concordances (supplemental Table 1).
In 2018, one of the four cases was excluded, as varying
TPS values were reported and no consensus outcome was
reached. Thus, six cases were included, two for every TPS
category. The reported laboratory settings and accreditation
statuses were validated on the websites of the laboratories
and their relevant national accreditation bodies [30].
Statistics were performed using SAS software (version 9.4
of the SAS System for Windows, SAS Institute Inc., Cary,
NC, USA).The relationship of the ESS on 5 points with lab-
oratory characteristics or used protocols was determined by
proportional odds models, presented as odds ratios (OR) with
95% confidence intervals (CIs). The incidence of analysis
failures and incorrect TPS estimations related to the ESS and
laboratory characteristics was assessed by Poisson models
with incidence rate ratios (IRR) with 95% CIs, with the log
of the number of EQA samples as an offset variable.
Generalized estimating equations (GEE) accounted for clus-
tering in the data (i.e., tests performed by the same laboratory).
‘Approved methods’ were defined as CE-IVD-labeled FDA-
approved CDx or complementary diagnostics without a
change of protocol. The number of EQA participations, sam-
ples tested annually, or involved staff members were consid-
ered as ordinal variables (instead of categorical) to evaluate
the influence of a +1 level increase.
Results
In 2017 and 2018, 67 and 74 laboratories participated respec-
tively, resulting in 141 EQA participations from 104 unique
laboratories in 30 different countries. The average ESS signif-
icantly (p < 0.01) improved between 2017 and 2018 from 3.8
to 4.3 points (Table 1); however, there was no significant
difference (p = 0.2859) between laboratories who participated
for the first (4.0) or second (4.2) time.
Almost half of the 141 participants (49.6%) were university
and research (such as specialized cancer centers) laboratories,
compared with 25.5% of laboratories affiliated to a general
hospital, 22.0% private laboratories, and 2.8% industry labo-
ratories. More than half (54.6%) were accredited for PD-L1
IHC specifically or on a laboratory level according to ISO
15189 or relevant national standards (e.g., College of
American Pathologists 15189). The majority of laboratories
(63/141, 44.7%) tested on average between 10 and 100 rou-
tine clinical samples annually for PD-L1, whereas seven par-
ticipants (5.0%) did not perform clinical testing. Between 1
and 5 (37.6%) or 6 and 10 (34.8%) staff members were most
frequently involved in performing and interpreting the PD-L1
IHC test. The abovementioned laboratory characteristics did
not correlate with the ESS in both EQA schemes (Table 1).
The participants stained and interpreted 423 cases in total,
of which 371 (87.7%) were correct (i.e., reported TPS was in
line with the pre-validated consensus value). In 8 (1.9%)
cases, an analysis failure occurred, meaning that the staining
could not be performed or interpreted. The TPS was under-
and over-estimated in 20 (4.7%) and 24 (5.7%) cases, respec-
tively. The majority of under-estimations occurred for a TPS
between 1% and 50%, close to the cutoff value of 1%, while
over-estimations where more evenly distributed across TPS
categories (Supplemental Table 1).
A lower ESS correlated with TPS under-estimations (p <
0.0001) in all cases and over-estimations (p < 0.0043) for
cases with a TPS between 1% and 50% (Fig. 1). Accredited
laboratories less frequently over-estimated cases (p < 0.05)
(Table 1), but there was no effect on under-estimations.
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Table 1 Laboratory characteristics related to average PD-L1 IHC ESS, analysis failures, and TPS misclassifications
Characteristic # observations (%)
(n = 141)
Average ESS on 5
points+






EQA scheme year 0.393 (0.217; 0.713);
p < 0.01**




2017 67 (47.5) 3.8 0 (0.0) 14 (70.0) 14 (58.3)
2018 74 (52.5) 4.3 8 (100.0) 6 (30.0) 10 (41.7)




ND 0.402 (0.135; 1.190);
p = 0.0998
1st participation 104 (73.8) 4.0 6 (75.0) 20 (100.0) 21 (87.5)
2nd participation 37 (26.2) 4.2 2 (25.0) 0 (0.0) 3 (12.5)
Laboratory setting†,‡ p = 0.8140 ND ND ND
Industry 4 (2.8) 4.3 0 (0.0) 0 (0.0) 3 (12.5)
(private) laboratories 31 (22.0) 4.0 6 (75.0) 4 (20.0) 5 (20.8)
Hospital laboratories 36 (25.5) 4.0 0 (0.0) 8 (40.0) 6 (25.0)
University and research 70 (49.6) 4.1 2 (25.0) 8 (40.0) 10 (41.7)








No 62 (44.0) 3.8 4 (50.0) 10 (50.0) 16 (66.7)
Yes 77 (54.6) 4.2 4 (50.0) 10 (50.0) 8 (33.3)
Missing data 2 (1.4) 4.5 0 (0.0) 0 (0.0) 0 (0.0)










No clinical testing 7 (5.0) 4.1 3 (37.5) 2 (10.0) 2 (8.3)
< 10 7 (5.0) 3.6 1 (12.5) 4 (20.0) 0 (0.0)
10-99 63 (44.7) 3.8 3 (37.5) 8 (40.0) 11 (45.8)
100-249 32 (22.7) 4.4 0 (0.0) 3 (15.0) 5 (20.8)
250-499 21 (14.9) 4.4 1 (12.5) 3 (15.0) 4 (16.7)
> 500 9 (6.4) 4.0 0 (0.0) 0 (0.0) 0 (0.0)
Missing data 2 (1.4) 4.5 0 (0.0) 0 (0.0) 2 (8.3)








1-5 53 (37.6) 4.0 3 (37.5) 6 (30.0) 8 (33.3)
6-10 49 (34.8) 4.0 5 (62.5) 8 (40.0) 9 (37.5)
11-20 23 (16.3) 4.1 0 (0.0) 4 (20.0) 5 (20.8)
> 20 14 (9.9) 4.4 0 (0.0) 2 (10.0) 1 (4.2)
Missing data 2 (1.4) 5.0 0 (0.0) 0 (0.0) 1 (4.2)








Approved kit (CDx) 67 (47.5) 4.2 2 (25.0) 11 (55.0) 10 (41.7)








No 25 (17.7) 4.2 1 (12.5) 0 (0.0) 3 (12.5)
Yes 12 (8.5) 4.3 1 (12.5) 0 (0.0) 0 (0.0)
NA 104 (73.8) 4.0 6 (75.0) 20 (100.0) 21 (87.5)
Antibody dilution p < 0.01** ND ND ND
< 1/50 17 (12.1) 4.3 0 (0.0) 1 (5.0) 2 (8.3)
1/50 - 1/100 72 (51.1) 3.9 7 (87.5) 9 (45.0) 12 (50.0)
> 1/100 14 (9.9) 3.4 0 (0.0) 4 (20.0) 4 (16.7)
RTU 38 (27.0) 4.5 1 (12.5) 6 (30.0) 6 (25.0)
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There was no relationship between other laboratory character-
istic and incorrect estimations.
For the 8 observed analysis failures, 3 were caused by 1
laboratory unable to interpret the cases as they were still val-
idating their protocol. Another 4 laboratories incorrectly indi-
cated that there were no tumor cells in the provided samples,
and 1 participant that their control stained negatively
(Supplemental Table 1). The relationship between failures
and ESS could not be calculated for cases with a TPS of
1%–50% and > 50% as only 1 failure was observed.
In total, 81/141 participants did not obtain the maximum
ESS of 5 on 5 points and received individual feedback. The
majority of issues observed included a very weak (28.4%) or
weak (34.6%) demonstration of the antigen in the tumor pop-
ulation, as well as slight (12.4%) or excessive (7.4%) back-
ground staining, not related to the used protocol
(Supplemental Table 2). Examples of most frequently ob-
served staining artifacts are given in Fig. 2.
The applied test methods for PD-L1 IHC significantly in-
fluenced the ESS. CE-IVD labeled or CDx kits (e.g., Ventana
PD L1 (SP142) Assay, Ventana PD L1 (SP263), and the PD-
L1 IHC 22C3 pharmDx) reached a higher ESS (4.2/5, n = 67)
compared with LDTs (3.9/5, n = 74) (OR1.916 [1.012; 3.626],
p < 0.05) (Table 1). To assess if a recent change in protocol
negatively affected the ESS, we evaluated the difference in
ESS for participants who did or did not change their method
between both schemes. Exactly 104 participants (73.8%) were
excluded as they were first time participants, and no method
information from previous years was available. For the re-
maining 37 laboratories, 12 changed their test method (either
the primary antibody, antigen retrieval, or detection method),
but no difference in ESS was observed (OR 0.899 [0.247;
3.280], p = 0.8723).
The use of a ready-to use (RTU) antibody dispenser
yielded significantly higher ESS compared with using a spe-
cific dilution factor between 1/50 and 1/100 (OR 5.025
Table 1 (continued)
Characteristic # observations (%)
(n = 141)
Average ESS on 5
points+






Incubation temperature (°C) 0.363 (0.193; 0.682);
p < 0.01**
ND ND ND
RT 55 (39.0) 3.7 1 (12.5) 10 (50.0) 14 (58.3)
30-37 86 (61.0) 4.3 7 (87.5) 10 (50.0) 10 (41.7)
Incubation time (min) p = 0.3784 ND ND ND
13-30 78 (55.3) 4.1 3 (37.5) 13 (65.0) 14 (58.3)
31-60 48 (34.0) 4.0 5 (62.5) 6 (30.0) 8 (33.3)
> 60 15 (10.6) 3.9 0 (0.0) 6 (30.0) 2 (8.3)
Use of amplification 1.249 (0.659; 2.365);
p = 0.4951
ND ND ND
No 77 (54.6) 4.1 6 (75.0) 10 (50.0) 12 (50.0)
Yes 64 (45.4) 4.0 2 (25.0) 10 (50.0) 12 (50.0)
Abbreviations: # number, CDx companion diagnostic, CI confidence interval, EQA external quality assessment, ESS expert staining score, GEE
generalized estimating equations, IHC immunohistochemistry, IRR incidence rate ratio, LDT laboratory-developed test, NA not applicable, ND not
determined, OR odds ratio, PD-L1 programmed death ligand 1, RT room temperature, RTU ready-to-use, TPS tumor proportion score
+Proportional odds models were used to analyze the difference in ESS. ++Poisson models were used to evaluate the association with analysis failures or
under-/over-estimations. Both models applied GEE for clustering of the data. Results are presented as ORs/IRRs (± 95% CI), respectively. OR/IRR > 1
represent a higher ESS/higher incidence for a higher category level. OR/IRR < 1 represent a lower ESS/lower incidence for a higher category level. *p <
.05, **p < .01, ***p < .001, ****p < .0001. ND; statistics not computed due to low power (absence or very few events in one level). For variables with
more than two categories (laboratory setting, incubation time, and temperature), overall significance levels are given. ORs for every pairwise comparison
between categories are described in the main text
°Analysis failures are defined as the failure to stain or interpret the PD-L1 IHC results on all assessed cases. Under-estimations are calculated on samples
validated as a TPS of 1–50% or > 50%. Over-estimations are calculated on the total number of samples with TPS < 1% or 1–50%
†Industry are laboratories involved in the development of diagnostic commercial kits. (Private) Laboratories are not within a hospital’s infrastructure.
Hospital laboratories included private and public hospitals. University and research included education and research hospitals, university hospitals,
university laboratories, and anti-cancer centers [30]
‡Laboratory setting and accreditation were validated on the websites of the laboratories and national accreditation bodies. Accreditation is defined as
compliant to ISO 15189 or relevant national standards
§Approved kits are defined as using the Dako 22C3, Ventana SP142, or Ventana SP263 kits with platform for their intended use. LDTs are defined as
these three clones in combination with another platform, or any other antibody clone
¶A switch included either the change in primary antibody, antigen retrieval, or detection method. ‘Not applicable’ included entries from first participa-
tions for which no method information from previous years was available
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[2.058; 12.346], p = 0.0004) or > 1/100 (OR 9.009 [2.169;
37.037]; p = 0.0024), but not compared with a dilution factor
of < 1/50 (OR 2.681 [0.924; 7.752]; p = 0.0696) (data not
shown). In contrast, incubation at room temperature (RT) re-
duced the ESS compared with higher temperatures (Table 1).
The incubation time or the use of amplification during detec-
tion did not alter the ESS. Because of the low frequency of
technical failures and misclassifications, their percentages are
given on a descriptive level only and no ORs are provided.
In total, the EQA participants used 32 different combina-
tions of primary antibodies, antigen retrieval, and detection
methods (Table 2). Out of 140 participations, the most widely
used primary antibody was the 22C3 antibody (Dako)
(56.7%), followed by SP263 (Ventana) (19.1%), and E1L3N
(Cell Signaling) (7.1%). The remaining 16.8% of participants
used less common primary antibodies, namely, 28-8 (Abcam,
2.8%), 28-8 (Dako, 2.8%), CAL10 (Biocare Medical, 2.8%),
QR1 (Quartett, 4.9%), and SP142 (Ventana, 3.5%) (Table 2).
We compared the most frequently used protocols with oth-
er protocols (Table 2). The SP263 (Ventana) CDx kit (with the
Cc1 antigen retrieval and OptiView DAB IHC Detection Kit)
displayed significantly higher ESS compared with all other
protocols (LDTs and approved kits) (Table 2, code d). The
most frequently used antibody, 22C3, yielded varying ESS
depending on the detection platform used. For instance,
22C3 in combination with less commonly used antigen re-
trieval and detection methods (not included in the CDx kit)
(Table 2, code c) resulted in significantly lower ESS compared
with 22C3 with reagents from the CDx kit (EnVisionFLEX
Target Retrieval Solution and Envision Flex detection meth-
od), or with the Optiview platform. We observed no other
statistical differences in ESS for the other methods.
Discussion
Detection of PD-L1 expression is a valuable biomarker in
NSCLC to select patients for ICI treatment [8]. Many studies
have emphasized the variation in techniques, positivity thresh-
olds, and staining concordance [15,23, 25, ].
This study for the first time correlated the ESS with the
different protocols, laboratories’ characteristics, and the inci-
dence of reporting an incorrect TPS.
First, our results confirm a wide variety of testing protocols
used across Europe not only for the primary antibodies but
also for the different detection methods, with an overall better
Fig. 1 Incidence of analysis failures and TPS under-/over-estimations
related to the obtained ESS. Poisson models with GEE were used to
analyze the association of the ESS with the number of incorrect TPS
classifications (under- or over-estimations) and the number of analysis
failures observed in the EQA schemes as count outcome variables.
Analysis failures are defined as the failure to stain or interpret the PD-
L1 IHC results. Under-estimations are defined only for samples validated
as a TPS of 1–50% or > 50%. Over-estimations are defined only for
samples with TPS < 1% or 1–50%. Results are presented as IRR (95%
CI) taking into account the log of the total number of samples analyzed
during the EQA scheme as an offset variable. Bar labels represent the
number of cases with correct results/under-estimations/over-estimations/
analysis failures observed. IRRs < 1 represent a lower number of
incidents for higher ESS. IRRs > 1 represent a higher number of
incidents for higher ESS. *p < .05, **p < .01, ***p < .001, ****p <
.0001. The IRR for analysis failures in cases with a TPS of 1–50% and
> 50% was not computed as only one incident occurred. Abbreviations:
CI confidence interval, EQA external quality assessment, ESS expert
staining score, GEE generalized estimating equations, IRR incidence
rate ratio, N/A not applicable, ND not determined, PD-L1 programmed
death ligand 1, TPS tumor proportion score
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staining concordance for FDA Cdx approved kits, compared
with LDTs.
It must be noted that the number of users in this study could
have contributed to the difference between CE-IVD kits and
LDTs, as the SP263 and 22C3 assays made up 17.0% and
22.7% (Table 2) of performed tests. Some antibody clones,
such as SP142 or other LDTs, had only a limited number of
users, and results should be interpreted with caution. The same
is true for other non-commercial antibodies reported in litera-
ture with a lower sensitivity than E3L1N, such as the 5H1,
7G11, 015, and 9A11 [32, 33], which were not assessed due to
an absence of users in these EQA schemes.
An explanation for better concordance of CE-IVD marked
kits might also include (i) the reduced inter-laboratory varia-
tion by restricting of the protocol in automatic software
deployers, (ii) the associated chemistry used to build these
assays [32], or (iii) difficulties in adhering to existing valida-
tion guidelines [25, 26, 34] for LDTs, as a gold standard for
PD-L1 assays and cut-offs is not available [33]. Additional
research into the different validation practices of the partic-
ipants might provide a better insight as to why LDTs are
currently underperforming. Some previous studies confirm
our results, in which fewer LDTs passed the quality control
compared with the clinically validated assays for PD-L1
[17, 27–29], and for ALK receptor tyrosine kinase IHC
[35, 36]. However, other studies reported a high concor-
dance of LDTs with reference assays [21, 37]. With the
change of the CE-IVD directive into a European IVD
regulation, more stringent validations need to be per-
formed for the kits to retain their label, possibly resulting
in more laboratories switching to approved kits [13, 38].
Continued data are thus needed to confirm the lower con-
cordance of LDTs in these EQA schemes.
Even though we compared the broad categories of LDTs
versus CE-IVD kits, we also observed variability within each
category, demonstrated by the higher concordance of the
SP263 CE-IVD kit compared with the 22C3 CDx kit, but also
the high concordance of the E1L3N primary antibody (Cell
Fig. 2 Examples of optimal and suboptimal concordance with PD-L1
IHC reference stains for different protocols during the 2018 EQA
scheme. Images represent a matching core with a validated consensus
TPS of > 50%. The core was part of a tissue micro-array containing
four different FFPE cases for staining by routine antibodies and
detection systems of the 2018 EQA participants. Protocols are
presented as reported by the participating laboratories. Scale bar 1 mm.
Optimal concordance (top row, from left to right): SP263: RTU antibody
from Ventana (16 min incubation at 36 °C) in combination with the
Ventana CC1 (64 min.) and OptiView DAB IHC Detection Kit. 22C3:
Antibody from Dako (diluted 1/40, 16-min incubation at 37 °C) in
combination with the Ventana CC1 (64 min) and OptiView DAB IHC
Detection Kit. 28-8: Antibody from Abcam (diluted 1/100, 32-min
incubation at RT) in combination with the Ventana CC1 (64 min) and
OptiView DAB IHC Detection Kit. SP142: RTU antibody from Ventana
(24-min incubation at 37 °C) in combination with the Ventana CC1 (48
min) and UltraView DAB IHC Detection Kit. E1L3N: Antibody from
Cell Signaling (diluted 1/200, 30-min incubation at RT) in combination
with Leica Bond Epitope Retrieval 2 (20 min) and bond polymer refine
detection system. Suboptimal concordance (bottom row, from left to
right): SP263: RTU antibody from Ventana (60-min incubation at 37
°C) in combination with the Ventana CC1 (64 min) and OptiView DAB
IHC Detection Kit; weak demonstration of antigen in the tumor
population and cytoplasmic staining. 22C3: Antibody from Dako
(diluted 1/50, 30-min incubation at RT) in combination with Dako
EnVisionFLEX Target Retrieval Solution (low pH) and the Envision
Flex detection system; Excessive background staining and cytoplasmic
staining. 28-8: Antibody fromAbcam (diluted 1/50, 20-min incubation at
32 °C) in combination with Dako EnVisionFLEX Target Retrieval
Solution (low pH) and the Envision Flex detection system; background
staining. SP142: RTU antibody from Ventana (16-min incubation at 36
°C) in combination with the Ventana CC1 (48 min) and OptiView DAB
IHC Detection Kit; weak staining of epithelial cells. E1L3N: Antibody
from Cell Signaling (diluted 1/150, 60-min incubation at RT) in
combination with laboratory developed antigen retrieval by TRIS-
EDTA and the Vectastain ABC immunoperoxidase staining avidin-
biotin complexes; weak demonstration of antigen in the tumor
population and cytoplasmic staining. Abbreviations: EQA external
quality assessment, FFPE formalin-fixed paraffin embedded, IHC
immunohistochemistry, PD-L1 programmed death ligand 1, RT room


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Signaling) compared with other LDTs. This is in line with
previously reported results, both for E1L3N [17] and for
SP263 [39].
Secondly, we observed an effect of antibody dilution and
incubation temperature, with higher concordance for RTU
antibody dilutions (compared with a dilution factor between
1/50 and 1/100) and for incubation between 30 °C and 37 °C
(compared with RT). However, that might be explained as the
majority of the data were derived from RTU antibodies as part
of CDx commercial kits. Although amplification has been
reported to alter the test outcome for expression levels near a
cut-off [40], we did not observe a difference.
Third, under- or over-estimations should be avoided, as
they could significantly alter the treatment options for pa-
tients. In this study, their absolute frequency was low, and
laboratories overall interpreted the PD-L1 IHC outcomeswell,
especially given that PD-L1 is a relatively novel marker and
increased error rates were reported during the introduction of
novel markers into practice [18, 30]. The TPS estimation was
however significantly affected by the ESS, resulting in under-
estimations for lower ESS. This emphasizes that rather than
interpretation of the obtained staining pattern, key to a correct
result is selecting an appropriate staining protocol with careful
validation and quality monitoring. Moreover, it is important
that both laboratories and EQA assessors calibrate the out-
come for each staining protocol with respect to the optimal
staining for that specific antibody.
The majority of misclassifications occurred at the threshold
cut-off, which is a well-known problem [39], mainly due to
weak demonstration of the antigen in the tumor population or
excessive background staining (Supplemental table 2),
resulting in the loss of the signal to background ratio. Even
TPS values differing by 20% or more compared with the val-
idated outcome were observed (Supplemental table 1).
Therefore, sample switches (e.g., confusion about which core
belongs to which case on the TMA) cannot be excluded.
In contrast to under-estimations, there was no significant
relationship between the ESS and analysis failures, and over-
all incidence of these failures was low. While 4 laboratories
indicated a lack of neoplastic cells in the sample, this could not
be confirmed by microscopic review of the slides by the as-
sessors, and peers who received slide sets from a similar po-
sition in the tissue block did not report any problems.
It must be noted that the schemes were performed on
TMAs with 1 or 3 cores per case, and might not completely
reflect the entire tumor microenvironment or PD-L1 expres-
sion on the invasive tumor front seen in routine practice [41].
Nevertheless, EQA results from the participants were corre-
lated to the received tissue section, and cases displaying het-
erogeneity were excluded from the concordance assessment
(Supplemental Figure 1).
Fourth, this is the first study to evaluate the relationship
between different laboratory characteristics and the ESS. We
observed a significant improvement over time from 3.8 to 4.3
on 5 points (p < 0.01). Even though second-time participants
had a higher ESS and fewer incorrect outcomes/analysis fail-
ures, results were not significant. It must be noted that only 37
laboratories participated in both schemes and the TMAs sent
in 2017 and 2018 were different (Supplemental Figure 1).
More longitudinal data are needed to confirm a positive effect
of repeated EQA participation and the feedback provided, as
previously suggested [42].
Interestingly, while accreditation was significantly associated
with fewer misclassifications, this was not the case for the ESS.
Even when using an optimal IHC protocol, interpretation of the
PD-L1 status might still be subjective based on the correct sep-
aration of membrane staining of the neoplastic cells versus non-
neoplastic epithelial cells, immune cells, and necrosis.
The fact that laboratory accreditation affected the interpreta-
tion, but not the staining concordance, suggests that laboratories
should participate in both aspects. From the EQAproviders’ side,
schemes should be fit-for-purpose to assess both staining concor-
dance and interpretation [43, 44]. Previously, interpretation of
PD-L1 IHC results has been described to improve upon pathol-
ogist training [17]. In our schemes, PD-L1 IHC was more fre-
quently performed in research institutes, but laboratory setting
and experience (number of samples tested, number of staff mem-
bers involved, and change inmethodology) did not correlate with
overall ESS or TPS interpretation, in contrast to previously re-
ported data [30]. As we included data from only two subsequent
EQA schemes, additional schemes might bring more clarity on
the effect of laboratory characteristics.
To conclude, the increasingly complex testing paradigm for
PD-L1 poses many challenges for pathologists and oncologists.
EQA participation could guide laboratories in obtaining better
concordance. The use of a CE-IVD kit according to the manu-
facturer’s instructions positively influences EQA concordance,
even though additional research is needed on less common pro-
tocols and non-automated techniques. In addition, EQA partic-
ipation should include a technical evaluation, given that lower
ESS was shown to be at the basis of TPS misclassifications,
rather than interpretation issues, and both aspects were different-
ly affected by the laboratory characteristics.
One of the advantages of the EQA schemes is the large
participants group for which a TPS estimation is available,
allowing to determine an optimal consensus TPS for every case,
and objectively comparing protocols by eliminating influences
of the pre-analytical phase (i.e., all participants receiving similar
and pre-validated slides). It remains to be elucidated how these
findings are reflected in routine settings, where different pre-
analytical variables and sampling of heterogeneous biopsies
can occur. Additionally, supplementing research on the errors
made (e.g., personnel errors when following the protocol,
clerical errors when reporting the outcomes) might reveal
shortcomings in individual laboratories leading to lower
concordance in the EQA scheme.
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